These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10735905)

  • 1. Primary systemic therapy in operable breast cancer.
    Wolff AC; Davidson NE
    J Clin Oncol; 2000 Apr; 18(7):1558-69. PubMed ID: 10735905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
    Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
    Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary systemic therapy in operable breast cancer: clinical data and biological fall-out.
    Maur M; Guarneri V; Frassoldati A; Conte PF
    Ann Oncol; 2006 May; 17 Suppl 5():v158-64. PubMed ID: 16807447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early operable breast cancer.
    Wolff AC; Davidson NE
    Curr Treat Options Oncol; 2000 Aug; 1(3):210-20. PubMed ID: 12057163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative (neoadjuvant) systemic treatment of breast cancer.
    Kaufmann M; von Minckwitz G; Rody A
    Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
    Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
    J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary systemic therapy of breast cancer.
    Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
    Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
    Kim R; Osaki A; Toge T
    Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
    Hofmann G; Balic M; Dandachi N; Resel M; Schippinger W; Regitnig P; Samonigg H; Bauernhofer T
    Clin Biochem; 2013 Oct; 46(15):1585-9. PubMed ID: 23792261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
    Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
    Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
    Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
    Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemotherapy for operable breast cancer.
    Mamounas EP; Fisher B
    Cancer Treat Res; 2000; 103():137-55. PubMed ID: 10948445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of radiation therapy on the use of primary ("neoadjuvant") systemic treatment of breast cancer].
    Souchon R; Dunst J; Hartmann KA
    Strahlenther Onkol; 2006 Apr; 182(4):202-9. PubMed ID: 16622621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.